Literature DB >> 27130897

Connexin 30 downregulates Insulin-like growth factor receptor-1, abolishes Erk and potentiates effects of an IGF-R inhibitor in a glioma cell line.

Sankaradoss Arun1, Arambakkam Janardhanam Vanisree2, Shantha Ravisankar3.   

Abstract

Connexins (Cx) play a crucial role in cell communication though regulation of cell growth and proliferation. In recent decades, both suppressive and enhancing roles of gap junction proteins in malignancy have been proposed, though mechanisms remain unclear. We intend to evaluate the impact of Cx30 on dysregulated growth of glioma owing to an aberrant expression of Insulin-like growth factor-1 receptor (IGF-1R). The study also examined whether Cx30 expression influenced sensitivity of glioma cells to Picropodophyllin (PPP), the potent inhibitor of IGF-1R. C6 cells transfected with full length Cx30 resulted in complete abolition of colony-forming efficiency. Interestingly, PPP-supplemented cells behaved differently with and without exogenous Cx as confirmed by wound closure assay. The expressions of phosphorylated and unphosphorylated IGF-1R along with its key signaling enzymes, pAkt/pErk, were also varied significantly in transfected and non-transfected C6 cells. pIGF-1R and IGF-1R were significantly reduced on Cx30 transfection when compared with that of non-transfected cells. pErk expression was abolished in transfected C6 with no significant difference in the expression of pAkt. The potency of PPP against C6 was more pronounced in the presence of Cx30. We demonstrate that Cx30 has the potential to alter the IGF-1R mediated pathway thereby influencing the growth, proliferation and migration of glioma cells which could further enhance the effect of therapeutic intervention. Though it could not be corroborated that the observations made are due to Cx30-mediated channel-dependent and/or independent impact, we stress the impact of significance of Cx30 on IGF-1R in glioma and also in therapeutic aspects.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C6 cells; Cell migration; Connexin30; Glioma; IGF-1R; Picropodophyllin

Mesh:

Substances:

Year:  2016        PMID: 27130897     DOI: 10.1016/j.brainres.2016.04.061

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Implication of connexin30 on the stemness of glioma: connexin30 reverses the malignant phenotype of glioma by modulating IGF-1R, CD133 and cMyc.

Authors:  Sankaradoss Arun; Shantha Ravisankar; Arambakkam Janardhanam Vanisree
Journal:  J Neurooncol       Date:  2017-09-05       Impact factor: 4.130

Review 2.  Targeting different domains of gap junction protein to control malignant glioma.

Authors:  Jun Wang; Ze-Yu Yang; Yu-Feng Guo; Jing-Ya Kuang; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

3.  Connexin 43 Loss Triggers Cell Cycle Entry and Invasion in Non-Neoplastic Breast Epithelium: A Role for Noncanonical Wnt Signaling.

Authors:  Sabreen Fostok; Mirvat El-Sibai; Dana Bazzoun; Sophie Lelièvre; Rabih Talhouk
Journal:  Cancers (Basel)       Date:  2019-03-08       Impact factor: 6.639

4.  Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy.

Authors:  Kuanyu Wang; Ruoyu Huang; Chenxing Wu; Guanzhang Li; Zheng Zhao; Huimin Hu; Yanwei Liu
Journal:  Oncol Lett       Date:  2019-10-29       Impact factor: 2.967

5.  Connexin 43 confers chemoresistance through activating PI3K.

Authors:  Kevin J Pridham; Farah Shah; Kasen R Hutchings; Kevin L Sheng; Sujuan Guo; Min Liu; Pratik Kanabur; Samy Lamouille; Gabrielle Lewis; Marc Morales; Jane Jourdan; Christina L Grek; Gautam G Ghatnekar; Robin Varghese; Deborah F Kelly; Robert G Gourdie; Zhi Sheng
Journal:  Oncogenesis       Date:  2022-01-12       Impact factor: 6.524

6.  Genome-wide expression profiling of glioblastoma using a large combined cohort.

Authors:  Jing Tang; Dian He; Pingrong Yang; Junquan He; Yang Zhang
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.